Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic

As the coronavirus disease 2019 (COVID-19; the disease caused by SARS-CoV-2) pandemic took hold in North America, rheumatology clinics across the continent were inundated with phone calls from patients with systemic lupus erythematosus (SLE) who were understandably fearful of COVID-19. One of the most common questions from patients was whether they should stop taking their medications. Since the beginning of the epidemic, turned pandemic, our immune-compromised patients with SLE have been overwhelmed with warnings of their higher risk of severe illness1,2. These statements are based on general knowledge of increased infection risk in patients with SLE, extrapolation from other viral illnesses, and expert opinion. However, adding to the confusion, there is no specific information on SLE per se or on any of the commonly used immunosuppressive drugs for SLE3. Even summary statements from those countries farther along the track of this pandemic broadly reference “patients with serious underlying disease” as being at high risk of poor outcomes without particulars4,5. Moreover, some very recent articles focus on the possible benefits of immunosuppressive drugs, both synthetic and biologic, to fight COVID-19, including early rumblings about the potential positive effect of chloroquine and hydroxychloroquine (HCQ)6,7. Then on Thursday, March 19, US President Donald Trump stated that antimalarials showed tremendous promise and “could be a game-changer.” Suddenly, the rumblings became a roar. The questions about stopping HCQ turned into “I can’t get HCQ, my pharmacy is out” from patients with SLE trying to access refills. All over Canada and the United States, news organizations were publishing stories of patients worried about drug supply, pharmacies documenting shortages, hospitals trying to stock up, drug companies promising to ramp up production, governments securing supply to treat patients with COVID-198,9, and even physicians stocking up for personal use10.

The benefits of antimalarials are proven for patients with SLE. In addition to managing skin and joint manifestations of SLE, antimalarials are known to prevent flares and reduce overall disease activity, reduce accrual of irreversible organ damage, reduce cardiovascular complications and thrombosis, and improve survival11,12,13. These comprehensive benefits have led to sweeping statements by SLE experts, recommending treatment with antimalarials “starting as soon as the diagnosis is made and maintained indefinitely (unless toxicity develops), regardless of the subsequent course of lupus, including pregnancy and any additional medications needed”11. With antimalarials now touted as one of the premier weapons against the global COVID-19 pandemic, and dozens of clinical trials starting up worldwide, along with off-label use outside clinical trials, demand has skyrocketed. What effect could a shortage of HCQ have on patients with SLE who rely on the drug to manage and stabilize their disease?

The first effect will undoubtedly be an increase in worry, anxiety, and illness uncertainty. Illness uncertainty is defined as the experience of living with continuous uncertainty from a chronic illness requiring ongoing management or with a possibility of recurrence14,15,16, and is already an important concept in SLE15,17. As expected, high uncertainty is associated with high emotional distress, anxiety, and depression1, and in SLE is shown to be inversely related to health-related quality of life17. No doubt the entire world is experiencing high levels of uncertainty at present. Mental health concerns are already rising, with talk of a parallel epidemic of fear, anxiety, and depression18,19. Patients with SLE already have very high levels of comorbid anxiety and depression, which are associated with worse SLE outcomes and higher symptom burden20. Further, there is mounting evidence that psychological stress, as seen in depression and anxiety, may contribute to inflammation in SLE. The mechanisms connecting emotional stress to immune dysfunction have been previously described: stress alters immune function through changes to the hypothalamic pituitary adrenal axis, which controls the stress response and cortisol secretion. Chronic exposure to cortisol downregulates glucocorticoid receptors, leading to reduced sensitivity of immune cells to cortisol’s inhibitory actions and consequently a state of chronic immune dysregulation21,22. In a study comparing 153 women with SLE to controls, serum levels of tumor necrosis factor-α were independently associated with both disease activity as measured by the Systemic Lupus Erythematosus...
Disease Activity Index (SLEDAI), and mood disorders. Pawlak, et al followed 41 female patients with SLE for 6 months and found that higher levels of daily stress were associated with increased disease activity as measured by the European Consensus Lupus Activity Measurement, and CH50 levels. Another study of stressors over a 6-month period in 46 patients with SLE found that a high percentage of patients with SLE reported a worsening in their clinical symptomatology because of the effects of daily stress; a subset of these with more prolonged symptoms had reductions in complement levels and increased levels of dsDNA antibodies. A second small study found that high levels of perceived stress in patients with SLE were associated with increases in SLEDAI score 4 to 5 months later. Could we then expect to see a surge of SLE flares as this pandemic progresses, related to the stress both of the pandemic and the disease, and compounded by fears of an HCQ shortage? Will it necessitate increased immunosuppressive medications, with an even higher risk for our patients with SLE?

There is a known risk of flare related to HCQ withdrawal. This was clearly demonstrated in the landmark study by the Canadian Hydroxychloroquine Study Group, where a randomized controlled trial of withdrawal of HCQ in patients with inactive SLE showed a 2.5-times higher risk of flare, as well as a shorter time to flare. The extension of this study also demonstrated increased risk of major flares requiring hospitalization after HCQ withdrawal. A more recent study similarly showed higher flare rates and a shorter duration to flare in patients with SLE discontinuing HCQ, and found an even higher risk of flare in those who have taken it for less than a year prior to discontinuation. Low blood concentrations of HCQ have been associated with flares of SLE in the following months, with nonadherence a major determinant of low blood concentrations. Studies show that HCQ provides protection from flares for 3 to 6 months following withdrawal; thus we know that some missed doses, or even a week or 2 without HCQ will not matter. However, if the pandemic goes on for months as predicted by many, and with the shortage of HCQ, then serious SLE flares will almost certainly result. Another unanswered question is the effect of dose reductions on the risk of SLE flares. Some patients may have to reduce their dose to maintain some level of protection in the face of shortages. Indeed, in Italy, where all hospitalized patients with COVID-19 are treated with HCQ and the resultant shortage at outpatient pharmacies is widespread, patients with SLE are advised to reduce their doses to maintain some degree of coverage (personal communication). Optimal doses of HCQ are not known, and many factors affect individual variations in blood concentration. However, there is a clear correlation between daily dose, blood concentration, and increased disease activity with risk of flare. Longterm dose reduction for some patients may carry a risk of serious flares similar to withdrawal.

One final and ironic possibility: is it possible that one outcome may be improved adherence to HCQ by patients with SLE? Part of what makes HCQ such an attractive prospect as a treatment for COVID-19 was summarized by Dr. Didier Raoult, an author of the French study at the heart of the current furor: “It is difficult to find a product that has a better established safety profile….Furthermore its cost is negligible”. For years, rheumatologists have been trying to convince patients with SLE of essentially the same thing. The risk-benefit ratio for HCQ is excellent, and the potential benefits significant. Yet adherence to HCQ is universally low. An early study aimed at demonstrating the relationship between blood concentrations of HCQ and clinical efficacy in patients with SLE found undetectable blood HCQ concentrations in a number of the patients, leading to the realization of severe nonadherence in a subset of these patients. Since then, multiple studies have shown high levels of very poor adherence, generally ranging from 20% to 50% of patients. Common reasons for poor adherence cited by patients include fear of adverse effects and lack of understanding of the benefits. It is possible that patients suddenly want to fill their previously neglected HCQ prescription? Will the positive light currently shining on antimalarials help to convince patients with SLE of the benefits? Will we see improved adherence? Only time will tell.

In the interim, rheumatologists caring for patients with SLE will need to provide reassurance if a few doses are missed, and evidence-based guidance on the use of HCQ for COVID-19, while joining the chorus of healthcare providers, patients, and advocacy groups urging protection of HCQ supply for patients with SLE.

Christine A. Peschken, MD, MSc, FRCP,
University of Manitoba Arthritis Centre,
Rady Faculty of Health Sciences,
Winnipeg, Manitoba, Canada.
Address correspondence to Dr. C.A. Peschken, University of Manitoba, RR149 Arthritis Centre, 800 Sherbrook St., Winnipeg, Manitoba R3A 1M4, Canada. E-mail: christine.peschken@umanitoba.ca

REFERENCES


Peschken: Editorial


First Release May 1 2020; J Rheumatol 2020;47:xxxxx; doi:10.3899/jrheum.200395